Belite Bio, Inc (NASDAQ:BLTE – Get Free Report) has earned an average rating of “Buy” from the seven research firms that are currently covering the company, MarketBeat Ratings reports. Seven analysts have rated the stock with a buy rating. The average 1 year price target among analysts that have covered the stock in the last […]